23-NET-01-VMT-PMC(VMT-alpha-NET-T101): A Phase I/IIa First-in-Human Study of [212Pb]VMT-alpha-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Grants and Contracts Details

StatusActive
Effective start/end date6/22/236/22/25

Funding

  • Viewpoint Molecular Targeting Incorporated: $68,956.00